Balyasny Asset Management
EDIT icon

Balyasny Asset Management’s Editas Medicine EDIT Stock Holding History

Balyasny Asset Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
+37,638
New +$110K ﹤0.01% 2872
2025
Q1 		– Sell
-1,300,604
Closed -$1.65M – 2903
2024
Q4 		$1.65M Buy
1,300,604
+1,126,569
+647% +$2.87M ﹤0.01% 1746
2024
Q3 		$593K Buy
174,035
+136,068
+358% +$592K ﹤0.01% 2199
2024
Q2 		$177K Sell
37,967
-254,743
-87% -$1.44M ﹤0.01% 2353
2024
Q1 		$2.17M Buy
292,710
+233,387
+393% +$1.94M ﹤0.01% 1522
2023
Q4 		$601K Buy
+59,323
New +$521K ﹤0.01% 1872
2023
Q1 		– Sell
-345,940
Closed -$3.07M – 2780
2022
Q4 		$3.07M Buy
345,940
+260,737
+306% +$2.86M 0.01% 1228
2022
Q3 		$1.04M Sell
85,203
-229,044
-73% -$3.57M ﹤0.01% 1777
2022
Q2 		$3.72M Buy
+314,247
New +$4.21M 0.01% 1075
2021
Q3 		– Sell
-29,902
Closed -$1.69M – 2063
2021
Q2 		$1.69M Buy
+29,902
New +$1.1M 0.01% 1076
2019
Q3 		– Sell
-118,993
Closed -$2.94M – 1272
2019
Q2 		$2.94M Buy
118,993
+90,126
+312% +$2.15M 0.02% 770
2019
Q1 		$706K Sell
28,867
-10,197
-26% -$231K ﹤0.01% 1109
2018
Q4 		$889K Buy
+39,064
New +$1.06M 0.01% 933
2018
Q3 		– Sell
-9,880
Closed -$354K – 1748
2018
Q2 		$354K Sell
9,880
-16,761
-63% -$593K ﹤0.01% 1461
2018
Q1 		$883K Buy
+26,641
New +$949K ﹤0.01% 1262
2017
Q1 		– Sell
-94,800
Closed -$1.54M – 1630
2016
Q4 		$1.54M Buy
94,800
+34,800
+58% +$528K 0.01% 931
2016
Q3 		$809K Buy
+60,000
New +$1.23M ﹤0.01% 700

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Balyasny Asset Management's EDIT Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Editas Medicine (EDIT) in Q2 2026: 37,638 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #2872 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in EDIT as recently as Q4 2024.

Balyasny Asset Management first reported a position in EDIT in Q3 2016 and has held it in 17 quarters since. The position peaked at $3.72M in Q2 2022. 216 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Balyasny Asset Management held 37,638 shares of Editas Medicine worth $122K as of Q2 2026.
  • Editas Medicine was a new Balyasny Asset Management position in Q2 2026.
  • Editas Medicine made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2872 holding.
  • Balyasny Asset Management first reported a position in Editas Medicine in Q3 2016 and has held it in 17 quarters since.
  • Balyasny Asset Management's Editas Medicine position peaked at $3.72M in Q2 2022.
  • 216 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.